GSK plc Sponsored ADR (GSK)
GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts
GSK PLC's (LSE:GSK, NYSE:GSK) $10.6 billion (£8bn) acquisition of US biotech Nuvalent has achieved something unusual in large pharmaceutical M&A: analysts broadly agree it makes sense. The debate is less about whether the deal is strategically sound and more about how much upside remains after shelling out a chunky amount for two relatively mature assets.
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
5 Things to Know Before the Stock Market Opens
Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, very good deal;" OpenAI has confidentially filed with the SEC for an IPO, but said in a statement it doesn't have a timeline for going public; Nuvalent shares are soaring after the drugmaker agreed to be acquired by British pharmaceutical giant GSK; and Vail Resorts shares are down after the company cut its outlook for the second time this year. Here's what you need to know today.
London's FTSE 100 falls as GSK slides after Nuvalent deal
The UK's benchmark FTSE 100 index moved lower on Tuesday, pressured by losses in healthcare giant GSK after the company announced plans to acquire shares of US-based drug developer Nuvalent in a deal valued at $10.6 billion. By 0810 GMT, the blue-chip FTSE 100 had slipped 0.3% to 10,341 points.
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
GSK agrees $10.6bn Nuvalent takeover to bolster oncology pipeline
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire US biotechnology company Nuvalent for $10.6 billion (£8.0 billion), adding "immediate" new sales growth opportunities, as well as a trio of advanced lung cancer drugs and other assets to boost its oncology pipeline. The FTSE 100 pharmaceuticals group said the deal would contribute to revenue growth from 2027 and be accretive to core operating profit in 2027 and core earnings per share in 2029, including synergies and reprioritisation.
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are currently under review by the FDA for approval this year.
UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion.
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, according to a Financial Times report. The companies have been in discussions with the aim of finalizing a deal as early as this week.
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports
UK pharmaceutical group GSK is in talks to buy cancer drugmaker Nuvalent for more than $9 billion, the Financial Times reported on Monday, citing people familiar with the matter.
US bank sees GSK oncology pipeline as major value driver after New York conference
Jefferies has flagged four near-term catalysts in GSK PLC's (LSE:GSK, NYSE:GSK) oncology pipeline following a fireside chat with the pharmaceutical company's global head of oncology and research and development at the bank's New York healthcare conference, reiterating its buy rating and 2,500p price target on the stock. GSK, which is trading at 1,872p, plans to present additional datasets for its B7H3 antibody-drug conjugate.
